Consano Bio to Present Clinical Development of C-1101 for Chronic Sciatica at 2026 BIO International Convention
BURLINGTON, MA — June 10, 2026 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced that Andrew Hall, Chief Executive Officer will present at BIO International Convention, being held June 22-25, 2026, in San Diego, California. READ MORE
Consano Bio Initiates Phase 1 Clinical Trial of C-1101, a Potential First-in-Class, Non-Opioid Therapy for Chronic Sciatica
BURLINGTON, MA — May 26, 2026 — Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to address serious painful orthopedic conditions, today announced that the first patient has been successfully dosed in its first Phase 1 clinical trial (C-1101-101, NCT07264270 ) evaluating C-1101 in patients with chronic, painful lumbosacral radiculopathy (LSR), also known as chronic sciatica. READ MORE
Consano Bio Presents Preclinical Data on C-1101 at ORS 2026 Annual Meeting
BURLINGTON, MA — March 30, 2026 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced the presentation of preclinical data supporting its lead investigational therapy, C-1101, at the Orthopaedic Research Society (ORS) 2026 Annual Meeting in Charlotte, NC. The data were presented in a poster session highlighting translational research on immunomodulation and neuropathic pain. READ MORE
Consano Bio to Present at BIO Investment & Growth Summit 2026
BURLINGTON, MA — February 23, 2026 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced that CEO Andrew Hall will present at the BIO Investment & Growth Summit, taking place March 2–3, 2026, in Miami, Florida. READ MORE
Consano Bio Highlights Scientific Advisory Board Supporting Clinical Development of C-1101 for Chronic Sciatica
BURLINGTON, MA — February 13, 2026 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today highlighted the role of its Scientific Advisory Board (SAB) in guiding the company’s scientific and clinical strategy as it advances C-1101 into clinical development for chronic lumbosacral radiculopathy (LSR), or chronic sciatica. READ MORE
Consano Bio Presents Favorable Nonclinical Safety Results for C-1101 at the American College of Toxicology 46th Annual Meeting
BURLINGTON, MA — November 21, 2025 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced positive data from its nonclinical safety and toxicology program for C-1101, supporting initiation of a Phase 1 clinical trial in patients with chronic painful lumbosacral radiculopathy (LSR), or chronic sciatica. The results were presented in a poster at the American College of Toxicology (ACT) 46th Annual Meeting in Phoenix, AZ. READ MORE
CORPORATE PRESENTATION
